MAIA Biotechnology presents next-generation telomere-targeting cancer drug candidates at IRT 2026

PUBT · 1d ago
MAIA Biotechnology presents next-generation telomere-targeting cancer drug candidates at IRT 2026
  • Maia Biotechnology disclosed preclinical results for next-generation telomere-targeting cancer candidates at IRT 2026 in Barcelona.
  • Data presented point to stronger anticancer activity for divalent prodrug designs versus ateganosine alone, supporting pipeline expansion efforts.
  • Work highlighted a strategy to combine telomere damage with a complementary DNA-targeting agent to lift efficacy across tumor types.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100815PRIMZONEFULLFEED9824003) on September 10, 2026, and is solely responsible for the information contained therein.